Physicians' Academy for Cardiovascular Education
The Heart Failure Association of the ESC has recently published a position paper on SGLT2i therapy in heart failure, beyond glycemic control.
1-year treatment with dapagliflozin reduced left ventricular mass (LVM) compared to placebo in T2DM patient with left ventricular hypertrophy, suggesting that dapagliflozin initiates cardiac reverse remodeling.
Prof. Wanner presents a case of a CKD patient who has developed diabetes. He discusses what the optimal treatment strategy for such a patient is and how new treatments have resulted in a paradigm shift in nephrology.
Nick Nurmohamed explains what Lp(a) is and how correction of LDL-c for Lp(a) reduces genetic testing for FH.
Treatment with the GLP-1RA dulaglutide for a median of 5.4 years resulted in a reduction of cognitive impairment compared to placebo in T2DM patients ≥50 years, in an exploratory analysis of REWIND.
The American Heart Association has published a scientific statement covering diagnosis and management of transthyretin amyloid cardiomyopathy (ATTR-CM).
Using data of the Lifelines Cohort Study including a contemporary adult population, this study showed that 30% of MIs in women are unrecognized vs. 16% in men.
Among asymptomatic phenotypic FH patients, patients with a genetically confirmed FH diagnosis had a higher frequency and severity of coronary atherosclerotic plaques, compared to those without a FH-causing mutation.
Treatment with 10 mg rivaroxaban reduces fatal and major thromboembolic events without significantly increasing major bleeding in medically ill patients after discharge, compared to placebo.
Using a case of a heart failure (HF) patient who was admitted to the hospital with acute decompensated HF (ADHF), two specialists discuss what the optimal treatment strategy in hospitalized patients should be during time of admission.
Presence of coronary artery calcium and risk of incident ASCVD events increased with increasing SBP levels in individuals with a SBP between 90 and 129 mmHg and no other traditional ASCVD risk factors.
Patients whose LVEF deteriorated from normal to midrange levels had a significantly higher risk of adverse clinical outcomes compared to those whose LVEF had improved from lower values.
